Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of “Moderate Buy” from Brokerages

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $35.70.

A number of research firms have recently commented on VRDN. HC Wainwright reiterated a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Monday, December 16th. TD Cowen started coverage on Viridian Therapeutics in a research note on Monday, November 25th. They set a “buy” rating on the stock. Royal Bank of Canada boosted their price target on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research note on Tuesday, December 17th. BTIG Research boosted their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a research note on Thursday, September 26th. Finally, Wells Fargo & Company restated an “equal weight” rating and set a $27.00 price target (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th.

Viridian Therapeutics Trading Down 5.0 %

Viridian Therapeutics stock opened at $18.20 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The business’s 50-day simple moving average is $20.54 and its 200-day simple moving average is $18.84. The firm has a market capitalization of $1.44 billion, a PE ratio of -4.22 and a beta of 1.13. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Equities research analysts forecast that Viridian Therapeutics will post -4.03 earnings per share for the current year.

Institutional Investors Weigh In On Viridian Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VRDN. Bank of New York Mellon Corp boosted its holdings in shares of Viridian Therapeutics by 37.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 208,676 shares of the company’s stock worth $2,715,000 after acquiring an additional 56,814 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Viridian Therapeutics by 24.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock worth $156,000 after acquiring an additional 2,359 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Viridian Therapeutics by 34.5% in the 2nd quarter. Rhumbline Advisers now owns 90,826 shares of the company’s stock worth $1,182,000 after acquiring an additional 23,305 shares in the last quarter. Arizona State Retirement System boosted its holdings in shares of Viridian Therapeutics by 14.7% in the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after acquiring an additional 1,688 shares in the last quarter. Finally, Candriam S.C.A. boosted its holdings in shares of Viridian Therapeutics by 167.8% in the 2nd quarter. Candriam S.C.A. now owns 749,804 shares of the company’s stock worth $9,754,000 after acquiring an additional 469,804 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.